

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**ESPS manuscript NO:** 19782

**Title:** Targeted therapy for advanced gastric cancer: A review of current status and future prospects

**Reviewer's code:** 00058438

**Reviewer's country:** Taiwan

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-05-22 09:45

**Date reviewed:** 2015-06-13 09:49

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

## COMMENTS TO AUTHORS

This study is a review article of targeted therapy for advanced gastric cancer, and the authors comprehensively reviewed results of clinical trials. The manuscript was well written, but I have some suggestions for improving its enrichment. Major comments: 1. If possible, Figure 1 could be made in color. 2. The contents of Table 2 should be rearranged according to "Line of treatment". 3. The section of "Conclusion and future prospects" should be further enriched. For example, the authors could focus on and summarize the targeted therapy strategies of current gastric cancer practice guidelines in a Table, such as Asia, ESMO and NCCN guidelines. 4. The authors could integrate targeted therapy and create a proposed flowchart in the management of gastric cancer. Minor comments: 1. In the "Introduction" section, "the vast majority of GC patients (65%) are found to have unresectable disease or distant metastases" is not true; for example, early gastric cancer is commonly found in Japan. 2. The outcomes of systemic chemotherapy are generally disappointed, so I suggest not using "gold-standard therapy" for chemotherapy in the "Introduction" section. 3. In the "Introduction" section, the authors declared that "trastuzumab and ramucirumab have been shown



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

to have a satisfactory clinical efficacy and safety profile". Although targeted therapy may prolong patient survival, but the progress is still not "satisfactory" in a long run.